Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. 
Introduction
Obstructive sleep apnoea is a common disorder that can present with or without symptoms and is accompanied by major neurocognitive and cardiovascular sequelae. [1] [2] [3] At present, care of patients with obstructive sleep apnoea varies by country and depends on a patient's symptoms. In well resourced settings, considerable efforts are being made to diagnose and treat individuals with obstructive sleep apnoea, but available data suggest that most cases of obstructive sleep apnoea remain undiagnosed and untreated, even in developed countries. In developing countries, there is generally little awareness of obstructive sleep apnoea, and diagnostic and treatment options are often not available or have not been adapted for resource-poor settings. 4 Because of the multifactorial and social consequences of obstructive sleep apnoea, the disorder is associated with a high economic and societal burden. In 2015, the cost of diagnosing and treating obstructive sleep apnoea in the USA was approximately US$12·4 billion. 5 The global cost of diagnosing and treating obstructive sleep apnoea has not been estimated because information about global prevalence is required first.
Evidence suggests that obstructive sleep apnoea is an important contributor to poor health outcomes and that treatment of this condition is generally beneficial in minimising the associated adverse clinical outcomes and improving sleep-related quality of life. 6 Thus, focusing on effective treatment of obstructive sleep apnoea might be one approach for reducing associated health-care costs and the negative impact of the condition, such as the cognitive impact of sleepiness. 7, 8 Additionally, given the shift in focus from issues around malnutrition and basic hygiene towards chronic health conditions, such as the obesity pandemic and its associated metabolic complications, [9] [10] [11] [12] the ageing population demographic, and the association between obstructive sleep apnoea and various non-communicable diseases, 14 obstructive sleep apnoea is likely to be a rising global problem over the coming years. 15, 16 Planning for effective diagnosis and management strategies requires accurate and country-specific estimates of disease prevalence. In 2007, WHO estimated that more than 100 million individuals were affected by obstructive sleep apnoea worldwide, 17 but this estimate was acknowledged to be only an approximation based on data available at the time. In this study we used a new approach and the latest publicly available data to estimate the global prevalence of obstructive sleep apnoea. We aimed to estimate the total number of affected individuals around the world and the proportion of those with moderate or severe obstructive sleep apnoea because positive airway pressure is recommended in all patients with excessive sleepiness, impaired sleep-related quality of life, and comorbid hypertension, which are more likely with an apnoea-hypopnoea index (AHI) of 15 or more events per h. 18 The aim of our analysis was to raise awareness of the global burden of obstructive sleep apnoea by providing data to help guide strategies and health policies to address this important health and societal problem, and to highlight substantial gaps in rigorously assessed obstructive sleep apnoea prevalence data that are currently unavailable for much of the global population. These gaps should be of great concern because of the wide-ranging negative sequelae of obstructive sleep apnoea.
Methods

Search strategy and selection criteria
We searched PubMed and Embase to identify prevalence studies of obstructive sleep apnoea done in the general or community population, in adults (aged 18 years and older), where obstructive sleep apnoea was measured objectively with a sleep study. We selected general population prevalence studies rather than those done in selected groups on the basis of concomitant diseases or those done in clinical settings where referral bias could be an important limitation. Only studies that used objective testing (rather than questionnaires) to diagnose obstructive sleep apnoea were included in our analysis. This included use of either home sleep testing (including airflow and oximetry) or in-laboratory polysomnography and reporting the AHI. We had no specific requirement for how obstructive sleep apnoea symptoms were evaluated or reported. The timeframe for studies was not limited in the search and the key words used in all combinations were "sleep disordered breathing", "sleep apnoea", "sleep apnoea syndrome", "obstructive", "prevalence", and "population". The original search was done in April, 2017, and then rechecked in February, 2019 (no new papers were identified in the second search). Reference lists of identified papers were manually reviewed. We applied no language exclusions so papers published in other languages were translated into English. Authors of the major studies identified were invited to collaborate. Our estimates focused on individuals aged 30-69 years because data for this group were generally available from the published studies and related to information from the UN for all countries. Therefore, the resulting prevalence estimates relate specifically to a subset of the global population aged 30-69 years.
Data collection and analysis
For studies that did not use the American Academy of Sleep Medicine (AASM) 2012 scoring criteria 19 to identify obstructive sleep apnoea, we created a conversion algorithm based on the study by Duce and colleagues 20 ;
Research in context
Evidence before this study Despite increasing recognition of obstructive sleep apnoea as a contributor to poor health outcomes, our literature searches identified a scarcity of data about global prevalence of obstructive sleep apnoea. We searched PubMed and Embase using search terms of "adult", "sleep disordered breathing", "sleep apnoea", "sleep apnoea syndrome", "obstructive", "prevalence", and "population", with no limits on timeframe nor any language restrictions. The original search was done in April, 2017, and then rechecked in February, 2019 (no new papers were identified in the second search). Relevant and local prevalence data are important to facilitate implementation of effective and efficient strategies for diagnosis and management of obstructive sleep apnoea.
Added value of this study
To the best of our knowledge, this is the first study to report a global estimate of obstructive sleep apnoea prevalence and to estimate the number of individuals affected by this condition worldwide. Nearly 1 billion adults aged 30-69 years worldwide were estimated to have obstructive sleep apnoea, with and without symptoms, based on an apnoea-hypopnoea index (AHI) cutoff value of five or more events per h, with 425 million (>45%) of these individuals having an AHI of 15 or more events per h (defined as a moderate to severe disorder requiring treatment). Wide geographical variation exists in the prevalence of obstructive sleep apnoea, with prevalence exceeding 50% in some countries.
Implications of all the available evidence
Given the high burden of obstructive sleep apnoea worldwide, health-care systems need to adopt effective diagnostic and management strategies so that the negative health impacts of obstructive sleep apnoea can be minimised. this approach allowed us to determine an equivalent AHI for publications that used different criteria: 21 Thus, we were able to report AHI figures based on the AASM 1999, AASM 2007, and AASM 2012 criteria, even if these criteria were not used in the original studies. 19, 22 The main differences between the criteria relate to scoring of hypopnoeas (table 1) .
An algorithm was developed in consultation with all authors to estimate global prevalence of obstructive sleep apnoea in individuals aged 30-69 years from the available published data. Prevalence for men and women was estimated separately and then combined to provide total prevalence. For countries with published prevalence estimates for obstructive sleep apnoea, these data were used. If no country-specific estimates were available, we matched countries without prevalence data to similar countries with prevalence data; determination of country population similarity was based on the population body-mass index (BMI; within 1 kg/m²), race (smallest difference in proportion of white, black, and Asian populations between the country being matched and the reference country or countries), and geo graphical proximity based on distance (appendix p 1). Age, sex, BMI, and race were used to match countries because these factors are clinically recognised to affect prevalence of obstructive sleep apnoea and these data were available for all countries. We obtained data on global estimates of BMI from the WHO Global Health Observatory data repository, data on race from the Central Intelligence Agency's World Factbook, and data on population-based age and sex from the UN World Population Prospects 2015. We evaluated the performance of our estimation procedure by comparing its performance in countries where prevalence data were available. Goodness of fit for these comparisons is shown in the appendix (pp 1-3). In two studies, the overall number of individuals used for the obstructive sleep apnoea prevalence estimates were reported, but not sexspecific numbers. In these cases, we assumed a 50:50 distribution between the sexes.
Our confidence intervals for the global estimate incorporate the sampling variability in the estimates of where N i is the population size of the i th subgroup (each subgroup is a sex in a specific country), K=386 (193 countries multiplied by 2 for both sexes) and p i is the obstructive sleep apnoea prevalence estimate applied to the i th subgroup. Since M=32 prevalence estimates were applied to the 386 population sizes (M is the number of reference prevalence estimates; 15 studies produced estimates for men and women, and two studies produced a single-sex estimate), the estimate can be rewritten by summing the population sizes of all subgroups to which each estimate was applied:
where M k is the total population size to which the k th obstructive sleep apnoea prevalence estimate was applied. The obstructive sleep apnoea prevalence estimate p k has variance p k (1 − p k )/n k , where n k is the number of individuals used to estimate p k . The individuals used in each prevalence estimate are independent; thus, the variance of the global estimate is Var(X), and the 95% CI is X ± 1•96√Var(X):
As a sensitivity analysis, an over-dispersed logistic regression model was fit to data from the prevalence estimate studies (each sex was modelled separately). The prevalence estimate of obstructive sleep apnoea was treated as the dependent variable; BMI and proportion of the white population were treated as continuous independent variables, continent was treated as a categorical independent variable, and an over-dispersion factor was added to the model to account for the wide variability across countries. This model then allowed for construction of a 95% CI that incorporated sampling variability in each study as well as the modelling errors in predicting each country's prevalence estimate. Since we found no studies of obstructive sleep apnoea prevalence in Africa, Africa was grouped with Oceania (similar estimates were obtained if Africa was grouped with Europe, North America, or South America). Statistical analyses were done with R software, version 3.3.
Role of the funding source
This work represents an academic and industry partnership. The study sponsor was involved in study design, data collection, data analysis, data interpretation, and writing of the report. All authors had full access to all the data and collectively made the decision to submit for publication. (table 2) . [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Reliable prevalence estimates were obtained on the basis of available data for 16 of 193 countries in the world; prevalence estimates for the remaining countries were extrapolated as described above.
Results
articles were included in the analyses
Using an AHI criterion of five or more events per h and the AASM 2012 criteria, an estimated 936 million (95% CI 903-970) individuals aged 30-69 years (men and women) worldwide were found to have obstructive sleep apnoea; the corresponding figure for an AHI of 15 or more events per h was 425 million (399-450; figure 1 ). The logistic regression model yielded a global obstructive sleep apnoea (AHI of five or more events per h) estimate of 730 million (618-842). Numbers of affected individuals were lower when the AASM 2007 criteria were applied and highest with the 1999 AASM criteria (figure 1). The estimated number of individuals with obstructive sleep apnoea was highest in China, followed by the USA, Brazil, and India; other countries in the top ten for the number of individuals with obstructive sleep apnoea were Pakistan, Russia, Nigeria, Germany, France, and Japan (figure 2), which predominantly reflects the overall size of the population of these countries. When expressed as a prevalence, the obstructive sleep apnoea burden for each country is shown as a heat map for an AHI of five or more events per h and an AHI of 15 or more events per h ( figures 3, 4) . A summary of the number of affected individuals and overall obstructive sleep apnoea prevalence for each country, region, or territory is provided in table 3.
Discussion
Our estimates suggest that nearly 1 billion adults aged 30-69 years worldwide could have obstructive sleep apnoea, and the number of people with moderate to severe obstructive sleep apnoea, for which treatment is generally recommended, is estimated to be almost 425 million. To the best of our knowledge, this analysis represents the first set of global estimates of the prevalence of obstructive sleep apnoea. Based on the published literature and by matching countries based on population demographics where specific data were not available, we estimated that almost 1 billion people worldwide aged between 30-69 years have an AHI of five or more events per h. The overall prevalence of obstructive sleep apnoea is likely to be higher given that the analysis focused only on adults aged 30-69 years and we used AASM 2012 criteria rather than the more liberal AASM 1999 criteria. 22, 40 The prevalence of obstructive sleep apnoea will be lower in adults younger than 30 years, and higher in adults aged 70 years and older, than we have estimated in this analysis, since previous publications show a linear relationship between age and obstructive sleep apnoea prevalence. 25 The number of individuals with moderate to severe obstructive sleep apnoea, based on an AHI of 15 or more events per h, was 425 million. This group could be considered the clinically important obstructive sleep apnoea population for whom treatment would be recommended, even though symptoms were not included in our estimate. We found that obstructive sleep apnoea prevalence estimates were dependent on the respiratory event scoring criteria used, but we focused on AASM 2012 19 because these guidelines are in widespread clinical use, and standardised data from different studies can be generated with a conversion factor. The optimal criteria for scoring is likely to depend on the technology used and the clinical outcomes of interest, but these variations are subtle compared with the large burden of disease that is undiagnosed at present. Based on the magnitude of these results, re-evaluation of the current AHI thresholds might be prudent when the latest sleep study scoring criteria and technologies are used in relation to clinical outcomes to identify the thresholds at which treatment is most appropriate. In 2007, WHO estimated that more than 100 million people worldwide were likely to have obstructive sleep apnoea. 17 However, to our knowledge, this value was acknowledged to be a gross approximation based on the data available at the time. We believe our approach of a country-imputation algorithm is a legitimate attempt to quantitatively synthesise the available evidence to estimate the global prevalence of obstructive sleep apnoea. Our approach used the major known factors that influence prevalence of obstructive sleep apnoea by matching on age, sex, BMI, and race, and, if required, geographical proximity, to identify the most suitable reference study to be applied to a country without introducing further assumptions. Both the primary country-imputation algorithm and the secondary logistic modelling approach led to global estimates that were much larger than those previously reported by WHO, although they were similar in magnitude to previously reported estimates. Increasing prevalence of obstructive sleep apnoea globally is consistent with single-country trends. 26 Various complex reasons probably underlie the discrepancy between our estimates and those from WHO in 2007, including the more precise methodological approach in our study and advances in detection technology. 41 Various population and population health factors are also likely to have had a role. Obstructive sleep apnoea is common in patients with high BMI 26, 42 and with increasing age. 26, 37, 42, 43 Therefore, the worldwide obesity epidemic and the ageing population demographic are likely to contribute to the rising global prevalence of obstructive sleep apnoea. Additionally, the high prevalence seen in countries such as China is likely to be due to racial and genetic differences in common anatomical features that increase the likelihood of obstructive sleep apnoea, such as a narrower airway. 44 The increasing burden of non-communicable diseases, such as diabetes, and more sedentary lifestyles could also have a role in the rising global prevalence of obstructive sleep apnoea. 45 Our analysis highlights the importance of considering how the burden of obstructive sleep apnoea should be managed. In countries where a diagnosis of obstructive sleep apnoea is less well recognised, education and advocacy are required to inform both patients and healthcare providers about this condition and its associated complications. 4, 46 In settings where technologies for diagnosing and treating obstructive sleep apnoea are not available, efforts to leverage alternative technologies to facilitate provision of cost-effective care need to be considered, along with strategies to improve accessibility. For example, wearable technologies, validated questionnaires, and connected devices could be used to optimise diagnosis. 47, 48 In this context, efforts are underway to try to diagnose obstructive sleep apnoea with simple devices that can be used anywhere in the world. 49, 50 Moreover, cloud-based technologies allow centralised reading and scoring of sleep tests so that local expertise is no longer needed to deliver appropriate diagnostic care. 48, 51 The high estimated global prevalence in this study suggests that the development of new and cheaper alternatives to diagnose and treat obstructive sleep apnoea are required.
For countries with well resourced health-care systems, delivery models whereby many patients can receive high-quality care without the need for multiple office visits with subspecialists need to be considered, along with alternative payment models. 52 For uncomplicated obstructive sleep apnoea, models of care are being developed that allow excellent clinical outcomes while potentially minimising costs. For example, Antic and colleagues 53 have shown that primary care physicians and nurse practitioners, under appropriate supervision, can achieve good outcomes in management of obstructive sleep apnoea. With the push towards costeffective care across the entire health-care system, efficient care delivery models are being increasingly discussed 52 and resources reallocated to multimorbid obstructive sleep apnoea. 54 Notably, although the diagnosis and treatment of sleep disorders can be viewed as a large economic burden, some health economic studies have suggested that management of obstructive sleep apnoea is not just cost effective but potentially cost saving as a result of prevention of major complications. [54] [55] [56] Nevertheless, the cost of treatment devices might be an important barrier to treatment in low-income and middle-income countries. To improve health equity, it might be necessary for global health bodies, including WHO, the UN, and non-governmental organisations, to lobby for provision of treatment devices for obstructive sleep apnoea at costs substantially lower than current pricing to facilitate access in developing regions.
The findings of our study need to be interpreted in the context of various limitations. First, although the goal of our analysis was to include as much published data from several countries and be as accurate as possible, we found no published prevalence data for obstructive sleep apnoea for most countries, including no countries from Africa. We therefore used techniques designed to provide the best estimates possible using available data from groups with similar demographic characteristics. This led to the reference studies being represented many times because of the nature of our country-imputation algorithm (ie, we used data from 16 countries to make estimates for 177 countries worldwide). Although we believe our global estimates are robust when compared with the countryspecific extrapolated estimates, individual country estimates were needed to generate the global estimate, so the country-specific estimates for those countries where no prevalence study was previously done should not be used in any formal way because these estimates might not be as precise as those for countries with available prevalence data. Additionally, we have not provided specific data for men and women or data about disease burden in different age groups. We hope that the data gaps identified in our analysis will help encourage more scrupulous epidemiological studies, particularly from regions where rigorous data are not currently available. Our sensitivity analysis, based on a logistic regression of the available data, yielded a lower estimate of the prevalence of obstructive sleep apnoea than the countryimputation algorithm (730 million vs 936 million) although it still confirmed a high prevalence of obstructive sleep apnoea. The logistic regression is lower because estimates from countries such as Singapore, Germany, and Switzerland are attenuated toward the means of their continent; the country-imputation algorithm does not reduce these estimates. Furthermore, logistic regression weights all predictor variables equally, whereas the country-imputation algorithm weights BMI as the most important factor in matching countries, racial distribution is a secondary factor, and geographical proximity is only used to resolve multiple matches on the first two predictors. This weighting of factors allows Australian men to be matched to Canadian men, for example, which would not be feasible in the logistic regression model. The logistic regression model also estimated that Asian countries similar to Singapore (BMI 24·2 kg/m², 9% white) have an obstructive sleep apnoea prevalence of 16·7%, whereas the country-imputation algorithm estimated these countries' prevalence as being 62·3%, as reported by Tan and colleagues. 36 These were the major drivers for the difference in the global estimate between the country-imputation algorithm and the more generalised logistic regression model. Second, we recognise that the parent studies from which we derived our estimates also have their own limitations, including first night effect, degree of sleep deprivation, body position, night to night variability, and participation and selection bias. Participation bias is an issue with many epidemiological studies and cannot easily be addressed with changing study design. Selection bias reflects the fact that people who are invited to participate might not be representative of the general population. This issue is amplified by the reliance on convenience samples rather than efforts to make sampling truly representative of the broader population. In acknowledging this limitation, we hope that new technologies will become available that might allow more consistent assessments of the general population.
Third, issues around methodological variability are clearly important, given the improved sensitivity observed with nasal pressure measurements versus with thermistor signals alone. 41, 57 Furthermore, pulse oximeters have variable time constraints and thus varying sensitivity and specificity for desaturation depending on equipment characteristics. Manual scoring of sleep studies is also likely to result in interscorer variability, especially in scoring arousals, which could affect hypopnea scoring and partly explain the variation seen in the published prevalence data for obstructive sleep apnoea. Re-scoring the raw data from the original studies according to consistent criteria would be challenging and standardisation of equipment from previous studies is not possible. Instead, we attempted to make estimates based on these known sources of variance. As a result, there are wide confidence intervals around our estimates based on strict versus liberal criteria. Nonetheless, we are aware that much higher prevalence figures could be generated depending on the assumptions used. None of the limitations mentioned here were considered in calculation of the 95% CIs; these intervals only reflect the sampling variability due to the study sizes used to estimate obstructive sleep apnoea prevalence. The confidence intervals do not reflect uncertainty in the obstructive sleep apnoea prevalence estimates for each country. The goodness of fit of the country-imputation algorithm was assessed as a cross-validation; this analysis indicates a potential underestimation of the global obstructive sleep apnoea prevalence (of up to -48%). A sensitivity analysis, based on a logistic regression model, indicated a potential overestimation of up to 28%. However, the logistic regression models severely underestimated prevalence of obstructive sleep apnoea in Singapore, Germany, and Switzerland. Clearly, estimating obstructive sleep apnoea prevalence in 193 countries based on sleep studies from just 16 countries will be subject to some error. These estimates can be refined when further data become available. Despite these limitations, our findings address an important gap in the published literature with regard to reporting comprehensive prevalence data for obstructive sleep apnoea.
In conclusion, this analysis highlights the high worldwide prevalence of obstructive sleep apnoea and variations by country and region. Additional, well designed studies are needed to investigate the prevalence of obstructive sleep apnoea, particularly in countries where published data are not available. This high prevalence and the documented association between obstructive sleep apnoea and numerous adverse clinical outcomes, including cardiovascular disease morbidity and mortality, mean that health-care systems around the world need to consider strategies to raise awareness of obstructive sleep apnoea and to diagnose and treat the condition to have a positive impact on population health and health-care expenditures.
Contributors
AM wrote the first draft of the report. AVB, KV, SRP, and AM did the analyses. AVB, NTA, PRE, RH, MSMI, MJM, CMN, SRP, TP, J-LDP, PEP, SS, ST, and KV reviewed and revised the manuscript before submission. All authors approved the final submitted version. 
Declaration of interests
Data sharing
All data included in this study are available in the public domain. Specific requests or questions should be submitted to the corresponding author for consideration.
